Senseonics partners with Welldoc to develop next-generation Eversense 365 mobile app
Senseonics Holdings, Inc.
Senseonics Holdings, Inc. SENS | 0.00 |
- Senseonics partnered with Welldoc to develop a next-generation mobile app for its Eversense 365 continuous glucose monitoring system.
- U.S. launch targeted for the second half of 2026; European availability planned for early 2027.
- App to keep current functionality, add tighter integration with Apple Health, Google Health Connect.
- Partnership also targets a redesigned interface to streamline sensor-transmitter setup, connectivity status, data displays, alerts.
- Companies expect follow-on releases, potentially adding AI-driven features such as bolus guidance, medication management, metabolic tracking.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senseonics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606100800PRIMZONEFULLFEED9734477) on June 10, 2026, and is solely responsible for the information contained therein.
